Clinical Trials
27 trialsPharmacokinetics of Daunorubicin in Young Patients With Cancer
Children's Oncology Group
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
Cancer Research UK
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Seattle Children's Hospital
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
Georgetown University
Bortezomib in Treating Children With Advanced Solid Tumors
National Cancer Institute (NCI)
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
Children's Oncology Group
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
National Cancer Institute (NCI)
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
Children's Oncology Group
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
Children's Oncology Group
Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
National Cancer Institute (NCI)
Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer
National Cancer Institute (NCI)
Pharmacokinetics of Dactinomycin in Young Patients With Cancer
National Cancer Institute (NCI)
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Registration and Informed Consent Study for the Childhood Cancer Research Network
Children's Oncology Group
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
Memorial Sloan Kettering Cancer Center
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
National Cancer Institute (NCI)
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
Bristol-Myers Squibb
Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Gemcitabine in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Gefitinib in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin in Treating Children With Advanced Solid Tumors
St. Jude Children's Research Hospital